Alexion Buys Out Portola, But Analysts Don’t See Value

The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.

SC2005_Time To Diversify_83066380_1200.jpg
Acquiring Portola and Andexxa diversifies Alexion's portfolio, but analysts don't see much growth potential

Alexion Pharmaceuticals Inc. revealed on 5 May that it has agreed to acquire Portola Pharmaceuticals Inc. for about $1.4bn in cash, but analysts don’t see the value in that price or in Portola’s Factor Xa inhibitor reversal drug Andexxa, a product stuck in neutral more than a year past its initial launch.

On a same-day investor call, Alexion executives cited multiple strategies for growing Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) and said...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Sino Biopharm Scoops LaNova In Chinese Pharma’s Biggest Biotech Buyout So Far

 

Sino Biopharm will pay almost $1bn to acquire what target LaNova’s CEO described as an “exploding” pipeline, which includes six clinical-stage candidates in the oncology area.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.

Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab

 

Plus deals involving Novartis/Sironax, Neuraxpharm/Dizlin, Recursion/RallyBio, MaaT/Clinigen, Future Pak/Theratechnologies, BerGenBio/Oncoinvent, Xoma/Turnstone and more.

China’s Mid-Cap Companies Thriving On Big Pharma Deals

 

Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.

More from Business